Ann: NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction, page-34

Last question in that interview:

Lauren Evans: And is there anything else that you'd like to add, James?

James Bonnar: One more thing, Lauren. In the study, we also ran an exploratory arm with a new compound we're developing, and we saw a really good reduction in cholesterol in the first 14 days. So, we're going to work on that compound as a potential backup or second-generation compound in parallel with putting NYX-PCSK9i through preclinical testing.

$50 mill market Cap, Directors loading up plus their Brian Injury Program.
Still have a little overhang from recent Cap raise but excellent opportunity at these prices!

Market definitely asleep on this one IMO!